April 13 (Reuters) – Allogene Therapeutics said on Monday that interim data from a mid-stage study showed its experimental off-the-shelf CAR-T therapy reduced the risk of cancer relapse in patients with blood cancer.
The company was testing its allogeneic, or “off-the-shelf,” CAR-T therapy in patients with a type of blood cancer whose disease remained detectable even after their initial round of standard treatment.
The CAR-T therapy, named cema-cel, utilizes white blood cells, specifically T-cells, from healthy donors.
These cells are re-engineered to create cancer-fighting immune cells. This treatment is pre-manufactured and readily available for administration to patients.
This differs from currently approved CAR-T therapies, which require collecting and genetically modifying a patient’s own immune cells, with reinfusion occurring weeks later.
(Reporting by Sneha S K in Bengaluru; Editing by Tasim Zahid)
Brought to you by www.srnnews.com